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RUNNING HEAD: Changes in hepatic disposition at low temperature 18 
19 
 2 
Objectives.   The aim of this study is to determine the factor changing the hepatic 20 
disposition of a drug during hypothermia using rat liver perfusion system. 21 
Methods.   The liver of male Wistar rats was perfused at 37°C, 32°C, or 28°C in the 22 
single-pass mode.   Venous outflow dilution patterns and biliary excretion rate patterns 23 
of phenolsulfonphthalein (PSP), indocyanine green (ICG) and fluorescein 24 
isothiocyanate (FITC)-dextran (FD-4, MW 4400) after the injection of a bolus into the 25 
perfused rat liver were analyzed based on statistical moment theory. 26 
Key findings.   The first-pass extraction ratio (Eh) of PSP was significantly decreased 27 
at 32°C and 28°C compared to 37°C.   The biliary recovery of PSP and its conjugate 28 
were decreased and their biliary excretion kept high concentration and prolonged by low 29 
perfusion temperatures.   ICG was almost extracted by a single-pass through the liver 30 
even at 32°C and 28°C.   The biliary recovery of ICG was significantly decreased at 31 
low temperature.   Although the distribution volume of FD-4 as a vascular reference 32 
was not changed by perfusion temperature, the Eh of FD-4 was decreased at 28°C 33 
although not markedly. 34 
Conclusion.   The change in hepatic disposition of a drug at low perfusion 35 
temperatures differed according to disposition processes under hypothermia. 36 
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Hypothermia is a therapeutic strategy used after cerebral ischemia and cardiac 42 
arrest to protect the brain.   Although several clinical studies have reported that 43 
treatment with hypothermia in patients with severe head injury, acute stroke, or hastened 44 
neurologic recovery improved the outcome (1-3), therapeutic hypothermia can have side 45 
effects such as arrhythmia, blood coagulation problems, and impaired immune function 46 
(4).   Several medicines such as anti- arrhythmic or antibiotics are administered to 47 
negate these effects.   Furthermore, alterations in the drug disposition of midazolam 48 
(5) and phenytoin (6,7) under hypothermia have been reported from clinical studies.   49 
However, there has been little systematic information concerning changes in the 50 
pharmacokinetics of drugs during hypothermia. 51 
In this study, we defined 32 and 28oC as hypothermia.   Because therapeutic 52 
hypothermia is done at 32-34oC, it is useful to know the alternation of hepatic 53 
disposition of drugs at 32oC.   Moreover, we examined the change of hepatic 54 
disposition at 28 °C, aiming to consider the unexpected conditions such as too much 55 
cooling and body temperature dependency on pharmacokinetic change of a drug in the 56 
patients fully by three different body temperatures. 57 
We have already reported that the pharmacokinetics of phenolsulfonphthalein 58 
(PSP), indocyanine green (ICG) and fluorescein isothiocyanate-dextran (FD-4, Mw 59 
4400) changed under hypothermic conditions in rats (8).   However, as many factors 60 
affect drug disposition such as blood flow, transporter and drug metabolizing enzyme, it 61 
is difficult to determine individual factors in studies in vivo.   It is necessary to 62 
determine the individual factors affecting drug disposition for prediction the 63 
pharmacokinetics during hypothermia.   Generally, the hepatic disposition of drugs 64 
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consists of four steps (i) uptake into liver from blood, (ii) efflux from the liver, (iii) 65 
elimination by metabolism and (iv) excretion into bile from liver.   Under the 66 
hypothermia, the activity of several transporters and enzymes could changed and this 67 
alternation affects on the hepatic disposition of drugs.   In this study, we tried to 68 
evaluate the effect of hypothermia on hepatic disposition by isolated liver perfusion.   69 
The isolated liver is often used to explore hepatic physiology and pathophysiology, 70 
because it is easy to control the flow rate and temperature of the perfusate. 71 
We chose PSP, ICG and FD-4 as model compound and these compounds 72 
eliminate by different process.   PSP is conjugated by enzymes and excreted into bile 73 
via multidrug resistance associated protein2 (Mrp2), while ICG is excreted via 74 
multidrug resistance P-glycoprotein2 (Mdr2).   On the other hand, FD-4 is eliminated 75 
by glomerular filtration from kidney and taken up into cell by endocytosis.   In this 76 
study, we can evaluate the effect of hypothermia on these transporter activities and 77 
transport process using PSP, ICG and FD-4.   In the present study, we examined the 78 
effect of temperature on hepatic disposition of three model compounds, PSP, ICG and 79 
FD-4 by isolated liver perfusion system to exclusive of another factor affecting the 80 
hepatic disposition, such as flow rate. 81 
82 
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MATERIALS AND METHODS 83 
Materials 84 
Phenolsulfonphthalein and indocyanine green were purchased from Nacalai 85 
Tesque, Inc. (Kyoto, Japan) and Daiichi Sankyo Pharmaceutical Co., Ltd. (Tokyo, 86 
Japan), respectively.   Fluorescein isothiocyanate-dextran (FITC-dextran) with an 87 
average molecular weight of 4400 (FD-4) was obtained from Sigma Chemical Co. (St. 88 
Louis, MO, U.S.A.). 89 
 90 
Animals 91 
Male Wistar rats (180-210 g) were housed in a cage in an air-conditioned room 92 
and maintained on a standard laboratory diet (MF, Oriental Yeast, Co., Ltd., Tokyo, 93 
Japan) and water ad libitum.   All animal experiments in the present study conformed 94 
to the Guidelines for Animal Experimentation of Nagasaki University and approved by 95 
Committee of Animal Experimentation of Nagasaki University (Approval number: 96 
0506280443). 97 
 98 
Liver perfusion 99 
Rat liver was perfused in situ as described by Mortimore et al. (9) with slight 100 
modifications.   Rats were anesthetized with sodium pentobarbital (50 mg/kg, i.p.).   101 
After the middle abdomen was cut open, the common bile duct was cannulated with a 102 
polyethylene tube (i.d. 0.28 mm, o.d. 0.61 mm, Becton Dickinson & Co., Parsippany, 103 
NJ, U.S.A.).   The portal vein was rapidly catheterized with a polyethylene tube (i.d. 1 104 
mm, o.d. 2 mm, Hibiki), and infusion of the perfusate, Krebs-Ringer bicarbonate buffer 105 
with 10 mM glucose (oxygenated with 95% O2-5% CO2 to pH 7.4 at 37oC), and was 106 
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started immediately.   The inferior vena cava was catheterized through the right atrium 107 
with a polyethylene tube (i.d. 1.7 mm, o.d. 2.7 mm, Hibiki, Tokyo, Japan) and then 108 
ligated right above the renal vein.    The perfusate was circulated using a peristaltic 109 
pump (SJ1211, ATTO Co., Tokyo, Japan) at a flow rate of 13.0 ± 0.2 mL/min (mean ± 110 
S.D.).   The experiments at low temperature were carried out with the perfusate 111 
maintained at 32oC or 28oC.   To avoid the effect of interaction with albumin and 112 
simplify the perfusion system, liver perfusion was carried out with albumin-free 113 
perfusate. 114 
After a stabilization period of 30 min, the drug solution (0.1 mL) was injected 115 
into the perfusion route.   After administration of the drug solution, venous outflow 116 
samples were collected into tubes at appropriate time intervals for 1 min.   The 117 
sampling interval was 1 sec at first and gradually prolonged.   Bile samples were 118 
collected into weighed test tubes at 5 min for 60 min.   The bile sample volumes were 119 
calculated from the gain in weight in the test tube assuming the density of the bile to be 120 
1.0.   The sampling time was taken as the midpoint of the sampling period.   After 121 
the perfusion experiment, the whole liver was excised and weighed.   The mean 122 
weight of the liver was 9.1 ± 0.9 g. 123 
 124 
Assay 125 
The concentration of model compounds in the venous outflow perfusate and 126 
bile sample was determined as follows.   The concentration of free PSP was 127 
determined spectrophotometrically at 560 nm after dilution with 1 M NaOH.   In the 128 
case of bile sample, the total concentration of free PSP and its conjugate was measured 129 
in the same manner after the samples were subjected to acid hydrolysis (1 M HCl at 130 
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100oC for 30 min) (10).   The concentration of PSP conjugate was estimated from the 131 
difference between these values. 132 
The concentration of ICG was determined spectrophotometrically at 805 nm 133 
after proper dilution with saline containing 0.1% (w/v) bovine serum albumin as a 134 
stabilizer. 135 
The concentration of FD-4 was determined spectrophotofluorometrically at 136 
excitation and emission wavelengths of 489 and 515 nm, respectively. 137 
 138 
Pharmacokinetic analysis of outflow patterns and biliary excretion rate-time 139 
curves 140 






dt Cauc        (1) 143 
 auctt ∫ ⋅=
∞
0 dt C       (2) 144 
where t is the time and C is the concentration of substances normalized by the injection 145 
dose as the percentage of the dose per milliliter, and auc and t  are the area under the 146 
concentration-time curve and mean transit time, respectively.   The moments were 147 
calculated by numerical integration using a linear trapezoidal formula and extrapolation 148 
to infinite time based on a monoexponential equation (11).   We chose two 149 
representative parameters, apparent distribution volume (V) and hepatic extraction ratio 150 
(Eh), to assess local drug disposition.   These parameters were derived from moments 151 
described previously (12) as follows: 152 
 FQV t⋅=        (3) 153 
 auc⋅= QF        (4) 154 
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 Q1Eh ⋅−= auc        (5) 155 
Where Q is flow rate of perfusate and F is the recovery ratio. 156 
The biliary excretion rate-time curves of free and conjugated PSP were 157 
analyzed independently based on the statistical moment theory (11).   In the case of 158 
ICG, a biliary recovery ratio (Fb,free) was determined, because the biliary excretion 159 
rate-time curve was not appropriate for the monoexponential extrapolation due to 160 
incomplete biliary excretion.   Biliary moment parameters for FD-4 were not 161 
calculated because of biliary excretion. 162 




















/)/( conjbconjbconjb aucdtdtdXtt     (9) 167 
doseaucF freebfreeb /,, =       (10) 168 
doseaucF conjbconjb /,, =       (11) 169 
where t is the time, and dXb,free/dt and dXb,conj/dt are the biliary excretion rates of free 170 
and conjugated PSP, respectively.   The values of dXb,free/dt and dXb,conj/dt are 171 
normalized with the injected dose per mL.   Fb,free and Fb,conj are the biliary recovery 172 
ratios of free and conjugated PSP, respectively.   freebt ,  and conjbt ,  are the biliary mean 173 
transit times of free and conjugated PSP, respectively.   The moments are calculated 174 
by numerical integration using a linear trapezoidal formula and extrapolation to infinite 175 
time based on a monoexponential equation, from the excretion rate-time curves. 176 
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Statistical Analysis 177 
Animal experiments were performed at least 3 times, and the mean and 178 
standard error (S.E.) were calculated.   Statistical comparisons were performed with 179 
Dunnett’s test after an analysis of variance (ANOVA).   p < 0.05 was considered to be 180 





Hepatic disposition of PSP at low perfusion temperatures 185 
Fig. 1 shows the outflow concentration-time curves of free PSP after a bolus 186 
was injected into the perfused rat liver at a dose of 0.1 mg under the different perfusion 187 
temperatures.   Table 1 lists the moment and disposition parameters for the outflow 188 
patterns.   The outflow peak concentration of free PSP increased according to the 189 
decrease in the perfusion temperature (Fig. 1), and auc increased to about 1.4 times that 190 
of the control condition, respectively, at perfusion temperatures of 32oC and 28oC (Table 191 
1).   The Eh of PSP was significantly decreased in the low perfusion temperature group 192 
compared to control, and V of PSP was also decreased according to the perfusion 193 
temperature. 194 
Figs. 2A, B illustrate the biliary excretion rate-time curves of free PSP and its 195 
conjugate after the injection of PSP at a dose of 0.1 mg under the different perfusion 196 
temperatures.   Similar to the change in Eh, the maximum biliary excretion rates of 197 
free PSP and its conjugate decreased according to the perfusion temperature.   Table 2 198 
lists the moment parameters for the biliary excretion rate of free PSP and its conjugate 199 
under the different perfusion temperatures.   The biliary excretion rates in 60 min for 200 
free PSP (Fb,free) and its conjugate (Fb,conj) in the low perfusion temperature group were 201 
decreased to about 50% of the control (Table 2).   In addition, the freebt ,  and conjbt ,  of 202 
PSP were significantly prolonged under the low perfusion temperatures. 203 
204 
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Hepatic disposition of ICG at low perfusion temperatures 205 
Table 1 lists the moment and disposition parameters for outflow patterns of 206 
ICG in the perfused rat liver at a dose of 0.1 mg under the different perfusion 207 
temperatures.   The -outflow patterns are not shown because of the extremely low ICG 208 
concentration in the outflow caused by the almost complete hepatic extraction of ICG 209 
(Table 1).   The auc values of ICG were extremely low (Table 1) compared to the 210 
other model compounds (Tables 1 and 4).   It was thus clarified that hepatic extraction 211 
of ICG was almost 100% even at low perfusion temperatures. 212 
Fig. 3A shows the biliary excretion rate-time curves of ICG after the injection 213 
of a bolus of 0.1 mg under the different perfusion temperatures.   The biliary excretion 214 
rate decreased with the perfusion temperature and either plateauted or continued to rise 215 
until 60 min at low perfusion temperatures.   As shown in Fig. 3B, the Fb of ICG in 60 216 
min at 28 and 32 oC was significantly decreased to less than about 40% of the control 217 
value. 218 
 219 
Hepatic disposition of FD-4 at low perfusion temperatures 220 
Fig. 4 shows the outflow patterns of FD-4 after a bolus was injected into the 221 
perfused rat liver at a dose of 0.1 mg under the different perfusion temperatures.   222 
There were no considerable changes among the perfusion temperatures in the outflow 223 
concentration of FD-4.   Moment and disposition parameters of outflow patterns of 224 
FD-4 are summarized in Table 1.   V of FD-4 as a vascular reference was unchanged 225 
under the low perfusion temperatures, and well correlated to the previously obtained 226 
data (12).   While the Eh of FD-4 at 32 oC was not changed, the Eh of FD-4 was 227 
significantly decreased at 28oC compared to 37oC. 228 
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DISCUSSION 229 
We performed single-pass rat liver perfusion experiments under different 230 
perfusion temperatures to examine the changing factors in vivo during therapeutic 231 
hypothermia.   The perfusion can be done independently of the influence of other 232 
organ systems, plasma constituents and neural-hormonal effects.   Compared with 233 
other in vitro models, however, the hepatic architecture, cell polarity and bile-forming 234 
capacity are preserved in the liver perfusion system. 235 
PSP, a hydrophilic dye (organic anion), has been clinically used to test renal 236 
function in humans, and is excreted into the bile and urine as a free form or conjugative 237 
metabolite in rats (10).   PSP is known to be taken up by organic anion transporter 238 
(OAT) (13) and excreted into bile via multidrug resistance associated protein2 (Mrp2) 239 
(14).   In the rat liver perfusion of PSP, Eh and V were significantly decreased by 40% 240 
at 28oC compared to the control condition.   The decrease of V was caused by the 241 
alternation of auc because the V was calculated by auc and t  (Eq. 3, 4) and then the 242 
auc of PSP was increased under hypothermia while the t  did not change (Table 1).   243 
In this study analyzed based on moment theory, we cannot evaluate the effect of 244 
hypothermia on influx and efflux process individually.   However, the increase of auc 245 
under hypothermia might be influenced by alternation of influx process because the 246 
peak concentration of PSP was increased (Fig 1). 247 
Moreover, we analyzed the biliary excretion of free and conjugated PSP in 248 
terms of metabolism in the hepatocytes and secretion from the hepatocytes into the bile.   249 
These processes were characterized by the biliary recovery ratio (Fb,free, Fb,conj) and 250 
biliary mean transit time ( freebt , , conjbt , ).   The biliary mean transit times of free and 251 
conjugated PSP were calculated to be 13.3 and 18.8 min and significantly prolonged 252 
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under hypothermia, respectively (Table 2).   In a previous study (8), the biliary and 253 
metabolic clearance of PSP were reduced under hypothermic conditions in vivo, 254 
correlating with the decreasing ratio of Fb,free and Fb,conj in the rat liver perfusion system.   255 
In addition, Fb,free/Fb,conj of PSP was not altered at 32oC while it was increased at 28oC, 256 
suggesting that the conjugation of PSP by enzymes was decreased at 28oC.   Because 257 
the drugs conjugated to glucronic acid is excreted into bile via Mrp2, the biliary 258 
excretion of these drugs could decreased during hypothermia in clinical. 259 
ICG has been widely used as a diagnostic drug to evaluate liver function, 260 
especially hepatic blood flow.   The characteristics of ICG are an intravascular 261 
distribution, a good capacity to bind blood protein, and excretion into the bile without 262 
biotransformation (15,16) via multidrug resistance P-glycoprotein2 (Mdr2) (17).   As 263 
listed in Table 1, the Eh of ICG was not affected by the perfusion temperature.   264 
Elimination of drugs such as ICG with a high intrinsic hepatic clearance depends largely 265 
upon hepatic blood flow, whereas the clearance of drugs such as PSP with an 266 
intermediate or low hepatic extraction ratio is much less dependent on alterations in the 267 
hepatic blood flow.   In a previous study (8), we clarified that total body clearance 268 
(CLtot) of ICG was markedly decreased under hypothermic condition in the rat in vivo, 269 
according to body temperature.   These results suggest that the decrease of hepatic 270 
blood flow was the changing factor of drugs with a high hepatic extraction ratio under 271 
hypothermic conditions. 272 
The cumulative biliary excretion of ICG in 60 min decreased considerably with 273 
the decrease in perfusion temperature (Fig. 3B).   The reduction in biliary excretion 274 
was likely another factor causing the decrease in CLtot.   The transepitherial transport 275 
of digoxin via multidrug resistant protein-1 (MDR1) was evaluated at various 276 
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temperatures in vitro using LLC-GA5-COL150 cells that expressed human 277 
P-glycoprotein specifically on the apical surface showed a multidrug resistant 278 
phenotype. (18).   According to this study, MDR1-mediated transport of digoxin 279 
decreased at lower temperatures.  ICG was excreted into bile by Mdr2, which is one of 280 
the ABC transporters, so the decrease in biliary excretion at low perfusate temperatures 281 
would be caused by changes in Mdr2 activity.   If the Mdr2 activity could decreased 282 
under hypothermia, the pharmacokinetics of digoxin and verapamil, which is substrate 283 
of Mdr2, might differ during hypothermia.   Furthermore, the reduction of ICG 284 
excretion into bile under hypothermia was larger than that of PSP.   This result 285 
suggests that the effect of hypothermia on Mdr2 might be greater than that on Mrp2.   286 
However, further studies are necessary for us to investigate the effect of hypothermia on 287 
ABC transporter activity by in vitro experiment. 288 
FD-4 is excreted mainly by glomerular filtration, and the contribution of 289 
hepatic extraction is very low. (19-21)   We used FD-4 as a vascular reference in the 290 
rat liver perfusion study.   It was reported that distribution volume of 131I-human 291 
serum albumin, another vascular reference substance, was not changed at 27oC, 292 
compared to 37oC. (12)   The auc and V were not changed under the low perfusion 293 
temperatures.   It was thus indicated that the distribution of FD-4 in the liver was not 294 
affected by perfusion temperature. 295 
The Eh of FD-4 was significantly decreased at 28oC compared to 37oC, while 296 
there was no change at 32oC, suggesting that the elimination of FD-4 by hepatic uptake 297 
leading to endocytosis was slightly decreased by the perfusion temperatures.   In case 298 
of FD-4, the prolongation of outflow pattern might be caused by slightly release of the 299 
FD-4 associated with the liver.   Moreover, the t  of FD-4 was larger than that of PSP, 300 
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it probably because of the difference in hepatic disposition between FD-4 and PSP.   301 
In the in vivo study (8), CLtot of FD-4 was significantly decreased at 28oC, probably 302 
because of decreased glomerular filtration as well as hepatic uptake leading to 303 
endocytosis. 304 
 305 
CONCLUSION  306 
We have demonstrated that the change in hepatic disposition of three model 307 
compounds under constant flow rate in the hypothermic group could differ with the 308 
disposition route and intrinsic clearance characteristics of the drug, probably due to 309 
decrease of transporter activity such as Mdr2 and Mrp2.   These results might be 310 
helpful for prediction of a pharmacokinetics during hypothermia. 311 
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Legend to Figures 374 
 375 
Fig. 1 Typical outflow patterns of PSP at a dose of 0.1 mg/liver after a bolus was 376 
injected in the single-pass rat liver perfusion system at 37oC (○), 32oC (▲) or 28oC 377 




Fig. 2 Biliary excretion rate - time curves of free PSP (A) and PSP conjugate (B) at a 381 
dose of 0.1 mg/liver in the single-pass rat liver perfusion system at 37oC (○), 32oC (▲) 382 




Fig.3  Biliary excretion rate-time curves of ICG (A) and Fb,free of ICG for 60 min (B) 386 
at a dose of 0.1 mg/liver in the single-pass rat liver perfusion system at 37oC (○), 32oC 387 
(▲) or 28oC (□).   Each point represents the mean ± S.E. and each column represents 388 




Fig.4 Typical outflow patterns of FD-4 at a dose of 0.1 mg/liver after a bolus was 392 
injected in the single-pass rat liver perfusion system at 37oC (○), 32oC (▲) or 28oC 393 




Table 1 Moments and representative disposition parameters for outflow patterns of free 397 
PSP, ICG and FD-4 after a bolus was injected in the single-pass rat liver perfusion 398 
system under different temperatures. 399 
 400 
Compounds Temperature (oC) 
auc 










































































Each value represents the mean ± S.E. for at least four experiments. 402 
*p<0.05, **p<0.01: significantly different from the results at 37oC. 403 
404 
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Table 2 Moment parameters for biliary excretion of free PSP and its conjugate in the 405 




(% of dose) 
freebt ,  
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Fb,conj 
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Fb,free and Fb,conj are the biliary recovery ratios of free and conjugated PSP, respectively. 408 
freebt , and conjbt ,  are the biliary mean transit times of free and conjugated PSP, 409 
respectively. 410 
Each value represents the mean ± S.E. for at least four experiments. 411 
**p<0.01; *p<0.05: significantly different from the results at 37°C.  412 
